|
Chemical Engineer, 1971, Univ. Porto; Master of Sciences (1975) and Philosophy Doctor (1979) Environmental Engineering, Imperial College of Science and Technology, U. London; Habilitation, Chemical Engineering (1991), Univ. Nova de Lisboa.
Full Professor, Chemical and Biochemical Engineering, Faculty of Sciences and Technology, Univ. Nova de Lisboa. Founder and earlier president (currently CEO) of IBET – Institute for Experimental and Technological Biology (www.ibet.pt), founder and board member of the Portuguese Academy of Engineering (1998-2001) and board member of the Euro CASE (Council on Applied Science and Engineering) (1998-2001), chairman of the European Society of Animal Cell Technology (ESACT) (1997-2001) and of Medical Biotechnology Section of the European Federation of Biotechnology (EFB) (1999-2001), member and Vice- Chairman of the External Advisory Group “Cell Factory” (Research Directorate General, European Commission) (1998-2002), member of the Advisory Board of Max – Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Amgen Bioprocessing Center, KGI, Claremont, California and CEVEC pharmaceuticals, Köln.
Founder and current CSO of GenIBET Biopharmaceuticals (www.genibet.com).
Meeting Chairman of the ESACT 14th Meeting “Animal Cell Technology: From Vaccines to Genetic Medicine”, Vilamoura, May 1996 and of the “3rd Recombinant Protein Production Meeting: A comparative view on host physiology", Tavira-Algarve (Portugal), November 2004. Visiting Professor at Carnegie-Mellon Univ. (1981), Massachusetts Institute of Technology - MIT (1988), Gesellschaft für Biotechnologische Forschung (1989 and 1993).
Supervised twenty-eight Ph.D. students (thesis defended) and published over one hundred seventy papers in refereed international journals; Associate-Editor of Journal of Biotechnology, member of the editorial board of Biotechnology and Bioengineering, Current Gene Therapy and Biotechnology Letters; referee of Biotechnology Progress, Cytotechnology, Applied Microbiology and Biotechnology, Enzyme and Microbial Biotechnology.
Key areas of research interest: Animal Cell Technology and its application for human and animal health (http://tca.itqb.unl.pt). Therapeutic and diagnostic recombinant proteins, including fusion proteins; virus like particles and pseudo viruses as vaccination agents and viruses (retro-, adeno-, lenti-) as deliverables for gene therapy; cell therapies and stem cells. cGMP pilot plant scale-up and production development of biopharmaceuticals. |
